Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours.
Qunfeng FuShuren ZhangSiyong ShenZhi GuJunyi ChenDongfan SongPengwei SunChunhong WangZhibin GuoYunlong XiaoYi Qin GaoZijian GuoZhibo LiuPublished in: Nature biomedical engineering (2024)
Pt(II) drugs are a widely used chemotherapeutic, yet their side effects can be severe. Here we show that the radiation-induced reduction of Pt(IV) complexes to cytotoxic Pt(II) drugs is rapid, efficient and applicable in water, that it is mediated by hydrated electrons from water radiolysis and that the X-ray-induced release of Pt(II) drugs from an oxaliplatin prodrug in tumours inhibits their growth, as we show with nearly complete tumour regression in mice with subcutaneous human tumour xenografts. The combination of low-dose radiotherapy with a Pt(IV)-based antibody-trastuzumab conjugate led to the tumour-selective release of the chemotherapeutic in mice and to substantial therapeutic benefits. The radiation-induced local reduction of platinum prodrugs in the reductive tumour microenvironment may expand the utility of radiotherapy.
Keyphrases
- radiation induced
- radiation therapy
- low dose
- endothelial cells
- high fat diet induced
- early stage
- stem cells
- high glucose
- high resolution
- type diabetes
- locally advanced
- magnetic resonance imaging
- squamous cell carcinoma
- cancer therapy
- insulin resistance
- early onset
- diabetic rats
- oxidative stress
- skeletal muscle
- drug delivery
- mass spectrometry
- pluripotent stem cells
- contrast enhanced
- dual energy